Publication Date:
1981-10-02
Description:
The growth in vitro of human breast cancer cells, line MCF-7, was inhibited by a daily supplement of L-arginine (1 milligram per milliliter). Arginine acted synergistically with dibutyryl adenosine 3',5'-monophosphate (cyclic AMP) (10(-6) molar) to enhance the growth inhibitory effect: the cell replication ceased completely within 2 days after treatment. The growth arrest accompanied a change in cell morphology and was preceded by increases in the cellular concentration of cyclic AMP, adenylate cyclase, and type II cyclic AMP-dependent protein kinase activities as well as a decrease of estrogen binding activity. The results suggest that growth of human breast cancer cells is subject to cyclic AMP-mediated regulation and that arginine may play a specific role in this process.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Cho-Chung, Y S -- Clair, T -- Bodwin, J S -- Berghoffer, B -- New York, N.Y. -- Science. 1981 Oct 2;214(4516):77-9.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/6269181" target="_blank"〉PubMed〈/a〉
Keywords:
Arginine/*pharmacology
;
Breast Neoplasms/metabolism/*pathology
;
Bucladesine/*pharmacology
;
Cell Division/*drug effects
;
Cell Survival/drug effects
;
Cells, Cultured
;
Cyclic AMP/metabolism
;
Drug Synergism
;
Female
;
*Growth Inhibitors
;
Humans
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
